SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Nymox Pharmaceutical Corp – ‘20-F’ for 12/31/18 – ‘EXCEL’

On:  Friday, 3/29/19, at 5:20pm ET   ·   For:  12/31/18   ·   Accession #:  1640334-19-464   ·   File #:  1-12033

Previous ‘20-F’:  ‘20-F/A’ on 5/11/18 for 12/31/17   ·   Next:  ‘20-F’ on 3/30/20 for 12/31/19   ·   Latest:  ‘20-F’ on 5/2/23 for 12/31/22

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/29/19  Nymox Pharmaceutical Corp         20-F       12/31/18  107:5.1M                                   Pubco Reporting … Inc/FA

Annual Report by a Foreign Non-Canadian Issuer   —   Form 20-F   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 20-F        Annual Report by a Foreign Non-Canadian Issuer      HTML    837K 
 4: EX-13.A     Annual or Quarterly Report to Security Holders      HTML     24K 
 5: EX-13.B     Annual or Quarterly Report to Security Holders      HTML     25K 
 2: EX-12.A     Statement re: Computation of Ratios                 HTML     30K 
 3: EX-12.B     Statement re: Computation of Ratios                 HTML     30K 
12: R1          Document and Entity Information                     HTML     58K 
13: R2          Consolidated Statements of Financial Position       HTML     86K 
14: R3          Consolidated Statements of Financial Position       HTML     27K 
                (Parenthetical)                                                  
15: R4          Consolidated Statements of Comprehensive Income     HTML     76K 
16: R5          Consolidated Statements of Changes in Equity        HTML     69K 
17: R6          Consolidated Statements of Cash Flow                HTML     90K 
18: R7          Business Activities and Basis of Presentation       HTML     36K 
19: R8          Going Concern Considerations                        HTML     29K 
20: R9          Significant Estimates                               HTML     27K 
21: R10         Significant Accounting Policies                     HTML     70K 
22: R11         New Accounting Standards and Interpretations        HTML     38K 
23: R12         Property and Equipment                              HTML     88K 
24: R13         Intangible Assets                                   HTML     28K 
25: R14         Accounts Payable and Accrued Liabilities            HTML     38K 
26: R15         Convertible Notes                                   HTML     39K 
27: R16         Commitments and Contingencies                       HTML     44K 
28: R17         Share Capital                                       HTML     40K 
29: R18         Stock Options                                       HTML     50K 
30: R19         Share Based Compensation                            HTML     36K 
31: R20         Warrants                                            HTML     58K 
32: R21         Income Taxes                                        HTML     75K 
33: R22         Earnings Per Share                                  HTML     34K 
34: R23         Financial Instruments Fair Value Disclosures        HTML     28K 
35: R24         Finance Income and Finance Costs                    HTML     48K 
36: R25         Segment Disclosures                                 HTML     43K 
37: R26         Concentrations                                      HTML     31K 
38: R27         Related Party Transactions                          HTML     39K 
39: R28         Research and Development Expenses                   HTML     39K 
40: R29         Personnel Expenses                                  HTML     36K 
41: R30         Capital Disclosures and Financial Risk              HTML     29K 
42: R31         Foreign Exchange Risk                               HTML     28K 
43: R32         Credit Risk                                         HTML     30K 
44: R33         27. Interest Rate Risk                              HTML     27K 
45: R34         28. Liquidity Risk                                  HTML     40K 
46: R35         29. Subsequent Events                               HTML     28K 
47: R36         Significant Accounting Policies (Policies)          HTML    121K 
48: R37         Significant Accounting Policies (Tables)            HTML     29K 
49: R38         Property and Equipment (Tables)                     HTML     87K 
50: R39         Accounts Payable and Accrued Liabilities (Tables)   HTML     36K 
51: R40         Convertible Notes (Tables)                          HTML     35K 
52: R41         Commitments and Contingencies (Tables)              HTML     43K 
53: R42         Share Capital (Tables)                              HTML     36K 
54: R43         Stock Options (Tables)                              HTML     55K 
55: R44         Share Based Compensation (Tables)                   HTML     33K 
56: R45         Warrants (Tables)                                   HTML     55K 
57: R46         Income Taxes (Tables)                               HTML     74K 
58: R47         Earnings Per Share (Tables)                         HTML     33K 
59: R48         Finance Income and Finance Costs (Tables)           HTML     47K 
60: R49         Segment Disclosures (Tables)                        HTML     42K 
61: R50         Concentrations (Tables)                             HTML     31K 
62: R51         Related Party Transactions (Tables)                 HTML     35K 
63: R52         Research and Development Expenses (Tables)          HTML     38K 
64: R53         Personnel Expenses (Tables)                         HTML     36K 
65: R54         Liquidity risk (Tables)                             HTML     38K 
66: R55         Significant Accounting Policies (Details)           HTML     33K 
67: R56         Property and Equipment (Details)                    HTML     61K 
68: R57         Property and Equipment (Details Narrative)          HTML     28K 
69: R58         Intangible Assets (Details Narrative)               HTML     37K 
70: R59         Accounts Payable and Accrued Liabilities (Details)  HTML     33K 
71: R60         Convertible Notes (Details)                         HTML     31K 
72: R61         Convertible Notes (Details Narrative)               HTML     39K 
73: R62         Commitments and Contingencies (Details)             HTML     36K 
74: R63         Commitments and Contingencies (Details 1)           HTML     33K 
75: R64         Commitments and Contingencies (Details 2)           HTML     35K 
76: R65         Commitments and Contingencies (Details Narrative)   HTML     38K 
77: R66         Share Capital (Details)                             HTML     29K 
78: R67         Share Capital (Details Narrative)                   HTML     38K 
79: R68         Stock Options (Details)                             HTML     50K 
80: R69         Stock Options (Details 1)                           HTML     43K 
81: R70         Stock Options (Details Narrative)                   HTML     29K 
82: R71         Share Based Compensation (Details)                  HTML     34K 
83: R72         Share Based Compensation (Details Narrative)        HTML     37K 
84: R73         Warrants (Details)                                  HTML     45K 
85: R74         Warrants (Details Narrative)                        HTML     35K 
86: R75         Income Taxes (Details)                              HTML     44K 
87: R76         Income Taxes (Details 1)                            HTML     32K 
88: R77         Income Taxes (Details 2)                            HTML     83K 
89: R78         Income Taxes (Details Narrative)                    HTML     28K 
90: R79         Earnings Per Share (Details)                        HTML     31K 
91: R80         Financial Instruments Fair Value Disclosures        HTML     26K 
                (Details Narrative)                                              
92: R81         Finance Income and Finance Costs (Details)          HTML     46K 
93: R82         Segment Disclosures (Details)                       HTML     43K 
94: R83         Concentrations (Details)                            HTML     32K 
95: R84         Related Party Transactions (Details)                HTML     37K 
96: R85         Related Party Transactions (Details Narrative)      HTML     36K 
97: R86         Research and Development Expenses (Details)         HTML     40K 
98: R87         Personnel Expenses (Details)                        HTML     36K 
99: R88         Capital Disclosures and Financial Risk (Details     HTML     41K 
                Narrative)                                                       
100: R89         Foreign Exchange risk (Details Narrative)           HTML     27K  
101: R90         Credit risk (Details Narrative)                     HTML     33K  
102: R91         Interest rate risk (Details Narrative)              HTML     26K  
103: R92         Liquidity risk (Details)                            HTML     37K  
104: R93         Subsequent Events (Details Narrative)               HTML     39K  
106: XML         IDEA XML File -- Filing Summary                      XML    195K  
105: EXCEL       IDEA Workbook of Financial Reports                  XLSX    100K  
 6: EX-101.INS  XBRL Instance -- nymx-20181231                       XML   1.72M 
 8: EX-101.CAL  XBRL Calculations -- nymx-20181231_cal               XML    142K 
 9: EX-101.DEF  XBRL Definitions -- nymx-20181231_def                XML    469K 
10: EX-101.LAB  XBRL Labels -- nymx-20181231_lab                     XML    895K 
11: EX-101.PRE  XBRL Presentations -- nymx-20181231_pre              XML    742K 
 7: EX-101.SCH  XBRL Schema -- nymx-20181231                         XSD    294K 
107: ZIP         XBRL Zipped Folder -- 0001640334-19-000464-xbrl      Zip    132K  


‘EXCEL’   —   IDEA Workbook of Financial Reports


This is an IDEA Workbook.

        Download this Microsoft® Excel® .xlsx workbook

Top
Filing Submission 0001640334-19-000464   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Apr. 23, 4:30:55.0am ET